Toggle light / dark theme

Advancing Geroscience & Gerotherapeutics — Dr. Nir Barzilai, MD, Albert Einstein College of Medicine.


Dr. Nir Barzilai, MD (https://www.einsteinmed.edu/faculty/484/nir-barzilai/) is the Director of the Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. He is the Ingeborg and Ira Leon Rennert Chair of Aging Research, professor in the Departments of Medicine and Genetics, and member of the Diabetes Research Center and of the Divisions of Endocrinology & Diabetes and Geriatrics.

Dr. Barzilai’s research interests are in the biology and genetics of aging, with one focus of his team on the genetics of exceptional longevity, where they hypothesize and demonstrate that centenarians (those aged 100 and above) may have novel protective genes, which allow the delay of aging or for the protection against age-related diseases. The second focus of his work, for which Dr. Barzilai holds an NIH Merit award, is on the metabolic decline that occurs during aging, and his team hypothesizes that the brain leads this decline with some very interesting neuro-endocrine connections.

Rejuvenating an older person’s blood may now be within reach, based on recent findings from Passegué’s lab published in Nature Cell Biology(link is external and opens in a new window).

Passegué, with her graduate student Carl Mitchell, found that an anti-inflammatory drug, already approved for use in rheumatoid arthritis, can turn back time in mice and reverse some of the effects of age on the hematopoietic system.

Nature article:

https://www.nature.com/articles/s41556-022-01053-0


Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

Green Tea Discount Link.
https://www.ochaandco.com/?ref=conqueraging.

Bristle Discount Link (Oral Microbiome Quantification):
ConquerAging15
https://www.bmq30trk.com/4FL3LK/GTSC3/

TruDiagnostic Discount Link (Epigenetic Testing)

How should we live when we know we must die? This question is posed by the first work of world literature, the Gilgamesh epic. More than 4,000 years ago, Gilgamesh set out on a quest for immortality. Like all Babylonian literature, the saga has survived only in fragments. Nevertheless, scholars have managed to bring two-thirds of the text into readable condition since it was rediscovered in the 19th century.

The Babylonians wrote in cuneiform characters on clay tablets, which have survived in the form of countless fragments. Over centuries, scholars transferred the characters imprinted on the pieces of clay onto paper. Then they would painstakingly compare their transcripts and—in the best case—recognize which fragments belong together and fill in the gaps. The texts were written in the languages Sumerian and Akkadian, which have complicated writing systems. This was a Sisyphean task, one that the experts in the Electronic Babylonian Literature project can scarcely imagine today.

Enrique Jiménez, Professor of Ancient Near Eastern Literatures at LMU’s Institute of Assyriology, and his team have been working on the digitization of all surviving cuneiform tablets since 2018. In that time, the project has processed as many as 22,000 text fragments.

This is more about the current landscape but a bit on the future near the beginning.


In this video Dr de Grey talks the future of LEVF and how the longevity field has evolved and some of the main participants.

Dr. Aubrey de Grey is internationally recognised as the visionary biomedical gerontologist who devised the Strategies for Engineered Negligible Senescence: a comprehensive set of methods to rejuvenate the human body, thereby preventing age-related ill health and mortality. He has co-founded multiple non-profit organizations – including Methuselah Foundation, SENS Research Foundation, and LEV Foundation – to enable and accelerate its development and clinical translation.